A review of systems that are currently in use to isolate and detect circulating tumor cells, in order to follow-up the clinical course of the disease and to monitor the response to therapy in oncological patients.
Tumor metastases account for approximately 90% of cancer-related deaths [1, 2]. Each malignancy has preferential organs and/or tissues for the metastatic dissemination and consequent colonization (Table 1) [3, 4]. The mechanism of the various steps that are involved in the metastatic process is still mostly unclear [5-7]. Overall, the multistep metastatic process involves the following stages: detachment of malignant cells from the primary tumor; extravasation of some cancer cells in the bloodstream; various factors promote the survival of a number of circulating tumor cells (CTCs) during the migration in the vascular system; another extravasation of malignant cells to distant organs and/or tissues; colonization and proliferation of disseminated tumor cells (DTCs) within the affected distant organs (Fig 1) [8]. In this scenario, CTCs may be considered an important factor that takes part in the dissemination of metastases in patients with cancer. The detachment of malignant cells from the primary tumor requires a gradual epithelial-mesenchymal transition (EMT) (Fig 2, panels A and B) [9]. Epithelial cells are polarized and interact with a basement membrane. EMT consists of various biochemical modifications to confer a mesenchymal-like cell phenotype to transformed epithelial cells (Fig 2, panels A and B). As the transition to the mesenchymal-like phenotype proceeds, modified and transformed epithelial cells tend to acquire enhanced invasiveness and migratory ability. At this stage, malignant cells detach from the basement membrane and can move away from the epithelial layer and become CTCs (Fig 2, panel A).
Type of malignancy | Major sites of metastases |
---|---|
Bladder | Bones, liver and lungs |
Colorectal | Liver, lungs and peritoneum |
Renal | Bones, liver, lungs, adrenal gland and brain |
Breast | Bones, brain, liver and lungs |
Ovarian | Uterus, liver, lungs, lymphatic system and peritoneum |
Cervical | Bladder, lungs, lymphatic system, bones and rectum |
Prostate | Bones |
Lung | Other lung, adrenal gland, liver, bones and brain |
Gastric | Oesophagus, liver, lungs and peritoneum |
Liver | Bones, lungs and brain |
Pancreatic | Liver, lungs and peritoneum |
Sarcoma | Lungs |
Melanoma | Skin, lungs, liver, bones, muscle and brain |
Uveal melanoma | Liver |
Thyroid | Bones, liver and lungs |
Current technologies allow for the isolation of CTCs from the peripheral blood of patients, which can be subsequently analyzed at the genetic and molecular level for the detection of tumor-associated genes and/or antigens [10, 11]. Protocols for the analysis of tumor associated markers in clinical samples have been described elsewhere. The isolation of CTCs from peripheral blood is essentially based on epithelial markers and other factors, which will be described in the next section (see “Enrichment, isolation and characterization of CTCs”).
The detection of CTCs in the peripheral blood of patients with cancer is a relatively easy system that does not involve an invasive intervention, such as biopsies from the patients [12]. Protocols have been clinically validated for the prognosis/staging of a variety of solid tumors, such as malignancies of the breast, prostate, colon, pancreas, lung, melanoma, glioblastoma or multiple myeloma [13]. Clinical studies are currently in progress to develop protocols for the monitoring of CTCs in patients with different types of sarcomas. For these types of malignancies, a major challenge arises from the lack of specific markers on the membrane of sarcoma cells. Circulating sarcoma cells are currently isolated either by using so-called non-specific parameters, or by detecting specific chromosomal translocations, which take place in transformed cells and are not present in normal tissues and/or cells. Such chromosomal translocations may result in the expression of fusion genes that can be detected by reverse transcriptase polymerase chain reaction (RT-PCR).
CTCs can be observed in the peripheral blood either as single cells, or in small clusters. CTCs clusters are more sporadic than single CTCs. Typically, the percentage of CTCs clusters is in the range of 2 to 5% of the total number of CTCs. CTCs clusters comprise more than two or three malignant cells and exhibit strong cell-to-cell adhesion. Some clusters may contain up to 100 cells. In addition to malignant cells, clusters include other cell types, such as cells of the immune compartment, platelets and tumor-associated fibroblasts. CTCs clusters are also termed microemboli. The formation of CTCs clusters, or microemboli, provides a microenvironment that protects to a certain extent circulating malignant cells from the action of the immune system, shear stress and anoikis, which is a type of apoptosis that may derive from the absence of cell adhesion [14]. Furthermore, circulating tumor microemboli may facilitate the colonization of the organ by DTCs. However, in spite of the mentioned protective functions of cell-to-cell adhesion, CTCs clusters exhibit shorter life span in the bloodstream than single CTCs, as shown by in vivo flow cytometry conducted on breast cancer patient-derived samples, which were subsequently injected into the tail vein of immunodeficient mice. In this animal model, the CTCs clusters clearance rates were three times faster than single CTCs. Probably, this finding can be attributed to the entrapment of CTCs clusters inside blood capillaries.
As revealed by clinical studies in patients with breast cancer and in animal models, CTCs clusters are highly metastatic [15-19]. These findings were also confirmed in patients with other tumors, such as advanced colorectal cancer [20, 21], pancreatic adenocarcinoma [22], melanoma [23], non-small cell lung cancer (NSCLC) [24, 25], small cell lung cancer [26] and prostate cancer [27]. Clinical studies are in progress to assess the diagnostic relevance of CTCs clusters, or microemboli, in other types of malignancies [28].
This review provides lists of reagents, along with the clinical protocols that can be used to isolate and monitor CTCs in various malignancies, in order to follow up the clinical course of the disease and to assess the response to the therapy.
The isolation of CTCs simply requires a sample of peripheral blood from oncological patients. CTCs are very rare and have a short half-life in the bloodstream. Usually, between 1 to 10 CTCs can be detected per milliliter of peripheral blood of patients with metastatic stage cancer [29, 30]. The ratio of CTCs and peripheral blood mononuclear cells may range between 1 to 105 and 1 to 106 [31]. For this reason, peripheral blood-derived CTCs fractions require an enrichment before they can be analyzed. Methods for enrichment and analysis are based on physical and/or biological properties of CTCs, such as size, deformability, density, polarity and electrical charge, epithelial cell adhesion molecule (EpCAM), cytokeratins (CKs) and tumor-associated markers expression [32]. CTC-derived cell lines can also be used [15, 33]. For example, Gkountela S et al obtained CTC-derived cell lines BR16, Brx50, Brx07, and Brx68 from other investigators to study CTC clusters [15].
EpCAM is a transmembrane glycoprotein that is expressed in epithelial and adenomatous cells and is overexpressed in a variety of carcinomas like prostate cancer [34, 35], whereas CKs are intermediate filaments that are present in the cytoplasm of epithelial cells [36, 37]. Epithelial markers render CTCs distinguishable from blood cells. However, epithelial markers expression decreases in CTCs with the progression of the epithelial mesenchymal transition (EMT) (Fig 2, panels A and B). On these grounds, some CTCs may not be detectable in various assays.
The main characteristics and drawbacks of detection and isolation systems for the analysis of CTCs are summarized in Table 2 and 3, respectively.
Modality of detection | Biomarkers utilized for CTCs analysis | Characteristics | Drawbacks |
---|---|---|---|
Immunocytochemistry, immunofluorescence | EpCAM EpCAM and CKs | Isolation of EpCAM-positive CTCs (epithelial origin). | Possible loss of CTCs with low levels of EpCAM expression. CTCs that have undergone advanced EMT may not be detected. |
Isolation of EpCAM(+)CK(+) CTCs and of EpCAM(-)CK(+) CTCs | CTCs that have undergone advanced EMT may not be detected. | ||
RT-PCR | Prostate specific antigen (PSA) for prostate cancer. Alfa-fetoprotein for liver cancer. Carcinoembryonic antigen (CEA) for colon cancer. Mucin-1 (MUC-1) for breast cancer. Human telomerase reverse transcriptase (hTERT) for gastric tumors. Cytokeratin (CK) 19 and CK 20 in colorectal cancer. | Higher sensitivity than immunocytochemistry. Presence of RNA is associated with alive cells. | False positives produced by nucleic acid contaminations. For various reasons, certain tumor-associated genes might be present in some normal cells and/or tissues. |
Fluorescence in situ hybridization (FISH) | Detection of genetic abnormalities that are associated with human cancer. | The optical imaging system Ikoniscope has enhanced the sensitivity of this assay. | Cells are no longer viable after FISH analysis. The interpretation of results may not be clear without Ikoniscope. |
Immunostaining-FISH, combined with subtraction enrichment (SE-iFISH) | Following SE (Table 2), iFISH allows for the in situ phenotyping and karyotyping of CTCs, along with the classification of various CTCs subtypes, via detection of tumor biomarkers expression levels. | Metafer-iFISH automated CTC imaging system provides a platform for the characterization of each CTC subtype in the progression of the clinical course of the disease. | Cells are no longer viable after iFISH analysis. |
Fluorescence assisted cell sorting (FACS) | Immunoglobulins for biomarkers, combined with forward and side scatters for the characterization of physical properties (cell size and internal complexity). | Versatile technique. Several parameters can be changed simultaneously. Wide range of applications. | Limited throughput, as cells are analyzed individually. Flow sorting conditions may be detrimental to certain cells. |
This method for CTCs enrichment from peripheral blood utilizes an inert polysucrose termed Ficoll (GE Healthcare Bio-Sciences, Pittsburg, PA; BD Biosciences, San Jose, CA), which was originally produced for the isolation of mononuclear blood cells from whole blood [38, 39]. The Ficoll protocol was then optimized for the separation of CTCs from blood cells and relies on differential migration properties that derive from diverse cell-type dependent buoyant densities [40]. A density gradient centrifugation system named OncoQuick is commercially available for the Ficoll-based separation of CTCs from peripheral blood [41] (Greiner Bio One, Frickenhausen, Germany). A flaw of the density-based cell separation method is the possible loss of some CTCs.
System | Modality of enrichment from peripheral blood | Identification procedure | Characteristics | Drawbacks |
---|---|---|---|---|
Ficoll | Cell density | Immunocytochemistry for CKs. RT-PCR for tumor-associated markers: Prostate specific antigen (PSA) for prostate cancer. Alfa-fetoprotein for liver cancer. Carcinoembryonic antigen (CEA) for colon cancer. Mucin-1 (MUC-1) for breast cancer. Human telomerase reverse transcriptase (hTERT) for gastric tumors. Cytokeratin (CK) 19 and CK 20 in colorectal cancer. | Density gradient centrifugation system is commercially available (OncoQUICK). | Possible loss of CTCs |
Size-based enrichment | Cell size and deformability, carried out with 10-cm silicon wafer devices, crescent-shaped isolation wells and micro-filters made of Parylene. | Immunocytochemistry, immunofluorescence, RT-PCR, FISH. | Microdevices are engineered for the optimal retrieval of CTTCs. | Tumor heterogeneity exhibits significant variations in malignant cells size. This may result in loss of CTCs during the analysis. |
RosetteSep | Negative enrichment by antibodies anti-human hematopoietic cells, which are linked to erythrocytes forming immunorosettes. Ficoll-Paque allows for the final isolation of CTCs. | Immunocytochemistry, immunofluorescence. | All components are commercially available. | This system requires two steps: immunorosettes formation and Ficoll-Paque gradient centrifugation. Possible loss of CTCs. |
Anti-CD45 immunomagnetic beads | Negative enrichment by ferromagnetic beads coated with anti-CD45 antibodies. | Immunocytochemistry, immunofluorescence. | CD45 is expressed in hematopoietic cells, with the exception of erythrocytes and plasma cells. Epithelial cells do not express CD45. This system is commercially available. | Possible loss of CTCs. Not all CD45(+) cells are removed, after the procedure. Possible presence of other impurities. |
Magnetophoretic mobility-based separation | Negative enrichment cells sorting. Cells are labelled with magnetic nanoparticles targeting CD34(+) CD45(+) hematopoietic cells, which are removed with a magnetic field of the Quadruple Magnetic Cell Sorter (QMS). | Immunocytochemistry, immunofluorescence. | QMS can sort 10 million cells per second, with a 99% depletion efficiency of CD34(+) CD45(+) peripheral blood cells. This system is commercially available. | After the procedure, other techniques are required for the isolation of pure CTCs populations. |
Magnetic activated cell sorting (MACS) and MagSweeper | Positive enrichment by immunomagnetic beads coated with anti EpCAM antibodies. | Immunocytochemistry, immunofluorescence. | EpCAM(+) CTCs can be isolated following a density gradient centrifugation step. The MagSweeper can automatically isolate EpCAM(+) CTCs. | Requires an initial density gradient centrifugation. MACS can isolate cells based only on a single target molecule. CTCs with low EpCAM expression and CTCs that have undergone advanced EMT are lost. |
Microfluidic devices | CTC-chips with anti-EpCAM antibodies | Immunocytochemistry, immunofluorescence | This system can detect CTCs with low EpCAM expression. | Possible loss of CTCs that have undergone advanced EMT. |
Fiber-optic array scanning technology (FAST) | A laser printing technique localizes rare subpopulations of immunofluorescent-labeled CTCs on glass substrates. | Immunofluorescence | Rapid detection and isolation of CTCs from large volumes of peripheral blood. The laser can excite 300,000 cells per second. Very wide field of view to monitor the emission spectrum. This system is 500-fold faster than automated digital microscopy; Suitable for the detection of early-stage tumors. Commercially available. | |
CellSearch | A ferrofluid linked to anti-EpCAM antibodies is utilized for the initial enrichment of EpCAM(+) cells, which are isolated with a magnetic field. | Immunofluorescence: PE-labelled anti-CKs antibodies APC-labelled anti-CD45 antibodies DAPI | Isolation and detection take place in a single step. CellSearch can efficiently detect EpCAM(+) CK(+) cells. Commercially available | Not suitable for CTCs that do not express epithelial phenotypes and that have lost EpCAM and CKs expression because of advanced EMT. May underestimate the number of CTCs [42, 43] |
Isolation by size of epithelial tumor cells (ISET) | Filtration through a membrane (8 mm diameter pores). Epithelial-derived CTCs stick to the membrane, whereas blood cells pass through. | Immunocytochemistry; cytomorphology | Sensitive assay. Commercially available. | Malignant cells may vary in size, because of tumor heterogeneity. For this reason, some CTCs may be lost. |
AdnaTest | Magnetic separation of EpCAM-positive cells, followed by RT-PCR for the identification of tumor-associated transcripts. | RT-PCR | Sensitive assay. Produced same CTCs enumeration results as CellSearch. Commercially available. | Cells are no longer viable after the assay, so they cannot be used for other types of analysis. RT-PCR may provide false positives, because of nucleic acid-related contaminations. |
EPISPOT | Detection of specific secreted proteins by enzyme-linked immuno-assays. Initial immunomagnetic depletion of CD45(+) cells, followed by immunomagnetic positive enrichment by selection of CXCR4(+) cells. Secreted proteins are spotted on a membrane and detected. | Enzyme-linked immuno-assay | MUC1 secretion was detected in 100% of patients with metastatic breast cancer. PSA was observed in 83.3% of prostate cancer patients. | This system is restricted to the analysis of CXCR4(+) cells. Not all malignant cells express CXCR4, because of tumor heterogeneity. |
Ariol system | Automated cell image capture for the analysis of CTCs placed on glass slides. | Immunofluorescence | The protocol was set up from the detection of breast cancer patients-derived CTCs. Allows for the detection of EpCAM(+) CK(+) and EpCAM(-) CK(+) CTCs. Commercially available. | Cells are not viable after the assay, so they cannot be used for other types of studies. Possible loss of CTCs that have undergone advanced EMT. |
Integrating antigen-independent subtraction enrichment (SE) | Non-toxic matrix with a specific density to remove red blood cells from white blood cells and CTCs after a centrifugation. White blood cells are depleted with anti-CD45 antibodies conjugated with magnetic beads. | Immunocytochemistry, immunofluorescence, RT-PCR, FISH, iFISH (see Table 2). | Cells remain viable following the removal of red blood cells. | Possible loss of CTCs that have undergone advanced EMT. |
This type of CTCs enrichment is based on size and deformability of epithelial cancer cells [44-46]. A 10-cm silicon wafer device was produced with standard micromachining techniques. This device consists of four segments of microfluidic channels placed on a silicon wafer, which are attached by adjacent little tanks that contain a fluid inlet and outlet [44].
Another microdevice contains multiple arrays of crescent-shaped isolation wells for the isolation of epithelial cancer cells from blood cells. Each trap has a gap of 5μm, which allows for the exit of blood components, including larger white blood cells that are more deformable than malignant cells. Prefilters with 20μm gaps prevent the clogging of the microdevice, by removing larger clumps and/or debris prior to the filtration. Microdevices are engineered to enhance hydrodynamic efficiency and to facilitate the optimal retrieval of CTCs.
A microfilter made of a parylene membrane was produced for the isolation, electrolysis and genomic analysis of CTCs. Parylene is provided by Specialty Coating Systems (Indianapolis, IN), or by Para-Coat Technologies (Johnstown, PA).
Size-based enrichment systems are limited by the significant variations in cell size among cancer cell populations, because of tumor heterogeneity [47]. This may result in the loss of some CTCs.
A negative enrichment technique consists of the depletion of most of the leukocytes and erythrocytes by means of RosetteSep (StemCell Technologies, Vancouver, BC, Canada), which utilizes antibodies that target hematopoietic cells of human whole blood and crosslink them to multiple erythrocytes. The crosslink, in turn, leads to the formation of immunorosettes. Centrifugation over the Ficoll-Paque buoyant density medium allows for the precipitation of immunorosettes and unbound red blood cells, while CTCs fractions can be recovered from the medium. This protocol is limited by the possible loss of some CTCs.
Ferromagnetic beads coated with anti-CD45 antibodies can be utilized as a further purification step of CTCs fractions derived from density gradient centrifugation procedures [48]. CD45 is a protein tyrosine phosphatase, receptor type, C (PTPRC) that is expressed on the membrane of hematopoietic cells, with the exception of erythrocytes and plasma cells [49]. CD45 is also missing in epithelial cells. Thus, anti-CD45 immunomagnetic beads bind only blood cells, which can be subsequently removed with a magnetic field. The capture efficiency of this protocol ranges from 52% to 88%. Anti-CD45 immunomagnetic beads are provided by Myltenyi Biotec (San Diego, CA) and Thermo Fisher Scientific (Monza MB, Italy). This technique is limited by the possible loss of some CTCs and by the presence of impurities, as not all CD45-positive cells are removed during the procedure.
In this negative enrichment cell sorting system, cells are labeled with magnetic nanoparticles. Magnetophoretic mobility is referred to the differential migration of magnetically labelled cells within a magnetic field [50]. A Quadrupole Magnetic Cell Sorter (QMS) was produced for the rapid enrichment and separation of CTCs from hematopoietic cells (Ikotech, Greenville, IN). QMS can sort 10 million cells per second, with a 99% depletion efficiency of CD34(+) and CD45(+) peripheral blood cells. This system allows only for the depletion of unwanted cells. After the enrichment step, other detection techniques must be applied for the isolation of pure CTCs populations.
This method is also known as magnetic activated cell sorting (MACS). Ferromagnetic beads coated with anti-EpCAM antibodies can be used to isolate CTCs, following a density gradient centrifugation step. EpCAM-positive CTCs can be automatically isolated with the MagSweeper, which utilizes a magnetic arm to harvest the ferromagnetic beads [51, 52]. The isolation of CTCs based on MACS depends on the single target molecule that is used in the protocol. In addition, some CTCs with low EpCAM expression and/or CTCs that have undergone advanced EMT might be lost.
In microfluidic devices, the blood flows on so-called CTC-chips that are made of equilateral triangle structures, which contain an assortment of anti-EpCAM antibody-coated microposts [53] or chips with other configurations such as graphene oxide chips [42]. Interestingly, microfluidific devices exhibit an efficacy of capture rate that is comparable among cancer cell lines with different levels of EpCAM expression [53]. For instance, in the first studies a group of investigators used a panel of human cancer cell lines with variable amounts of EpCAM expression, such as NSCLC NCI-H1650 and breast cancer SKBr-3 cell lines (with more than 500,000 EpCAM molecules per cell), prostate cancer PC3-9 cell line (with 50,000 EpCAM molecules per cell) and bladder cancer T-24 cell line (with roughly 2,000 EpCAM molecules per cell) [54]. Most likely, this finding is due to the increased interactions between cells and the substrate of the CTC-chip. However, the enhanced sensitivity for the capture of cell lines with low EpCAM expression might not be sufficient for the selection of biopsy-derived CTCs that have undergone advanced EMT.
A more advanced microfluidic system, CTC-iChip, combines size-based separation of nucleated cells (leukocytes and CTCs) from red blood cells, platelets and plasma, and depletion of magnetically labeled white blood cels to enrich CTCs [55]. Ebright RY et al, for exmaple, further stained the enriched products with EpCAM, cadherin 11, and HER2 antibodies for CTCs and with CD45, CD14 and CD16 antibodies for white blood cells to obtain individual CTC under a fluorescent microscope with an Eppendorf Transfer-Man NK 2 micromanipulator [56]. W Huang et al devised a similar size- and magnetics-based micro-aperture platform to capture both cells and plasma proteins in separate chambers [57]. M Radovich et al applied such a micro-aperture process to measure circulating tumor cells in order to evaluate the prognostic value of circulating tumor cells in breast cancer patients in a clinical trial [58].
This protocol was developed by Cytelligen, San Diego, CA. For the description of the protocol, see Table 3 and the paragraph “Integrating antigen-independent subtraction enrichment and immunostaining-FISH (SE-iFISH)”, under “Protocols for CTCs detection”.
Quantitative RT-PCR is the preferred nucleic acid-based method for the analysis of CTCs associated markers [59, 60]. The expression of messenger RNA implies that most likely cells were still alive at the time of the isolation and analysis. In fact, RNA is rapidly destroyed when cells die. In addition, studies showed that RT-PCR is more sensitive than immunohistochemistry for the probing of cell specific markers [61, 62]. Following CTCs isolation, quantitative RT-PCR was utilized for the detection of MUC-1 in breast cancer patients [63], alpha-fetoprotein (AFP) in primary liver cancer patients [64], human telomerase reverse transcriptase (hTERT) in patients with gastric tumor [65], cytokeratin (CK) 19 and CK 20 in colorectal cancer patients [66] and prostate-specific antigen (PSA) in patients with prostate cancer (Table 2) [67-69]. RT-PCR may be susceptible to provide false positives, because of sample contamination (Table 2) [70]. There is also the possibility that the target gene is expressed in some normal cells [70]. Another disadvantage of RT-PCR is that analyzed cells cannot be used for any other type of study.
This technique utilizes fluorescent labeled DNA probes to detect specific DNA sequences within certain chromosomes [71]. FISH analysis is very precise and can detect a variety of genetic abnormalities that are related to human illnesses [71, 72]. However, the experimental procedure requires highly trained personnel, is labor intensive and sometimes may not provide clear results. In this respect, an alternative optical imaging system named Ikoniscope® (Ikonisis, New Haven, CT) was developed to detect rare cell populations [73-75]. Interestingly, the Ikoniscope® imaging system can detect one CTC per milliliter of peripheral blood [75]. However, analyzed cells cannot be utilized for subsequent studies, as they are no longer viable after FISH analysis.
This technique relies on an enrichment step for CTCs, in which cells retain viability and are suitable for primary tumor cell culture conditions (Table 3). The enrichment step is followed by immunostaining for epithelial markers combined with FISH analysis for chromosomal aneuploidy (Table 2) [76]. SE-iFISH technology can be supported by Metafer-iFISH automated CTC imaging system, in order to provide a platform for the characterization of each CTC subtype in the progression of the clinical course of the disease.
The subtraction enrichment procedure utilizes a non-toxic matrix with a specific density to remove red blood cells from white blood cells and CTCs after a centrifugation (Cytelligen). Hypotonic solutions are not required in this protocol, which could potentially damage some epithelial-derived cells. White blood cells are then removed with magnetic beads conjugated with anti-CD45 antibodies.
The iFISH method allows for the in situ phenotyping and karyotyping of CTCs, along with the classification of various CTCs subtypes, following the detection of tumor biomarkers expression levels.
FACS relies on the use of antibodies and is commonly utilized for the separation of a specific cell type, which can be isolated with high purity from the general cell population [77]. Forward scatter and side scatter allow for the characterization of physical properties such as cell size and internal cellular complexity, respectively [77, 78]. An electrostatic detection system leads to the accurate isolation of a determined cell fraction, based on the electric charge of that particular cell population. Cellular electric charges depend on the specific genes that are expressed in each cellular context. Up to 50,000 cells per second can be sorted with advanced flow cytometers (Abcam, Cambridge, MA; BIO-RAD, Hercules, CA; BD Sciences, San Jose, CA). FACS is a versatile technique that has a wide range of applications, as several parameters can be simultaneously analyzed [79]. FACS has a limited throughput, as cells are sorted individually. FACS technology may be affected by another shortcoming. In some cases, flow sorting conditions may be detrimental to particular types of cells and, therefore, impede subsequent studies [80].
The Parsortix Cell Separation System employs microfluidic particle separation technology to capture tumor cells based on their large size and resistance to compressiona from bodily fluids (e.g., blood, bone marrow, and ascites) [81]. The capture does not require antibodies or other cell surface affinity agents; however, the captured cells can be directly stained inside the cassettes. Gkountela S et al, in their studies of CTC clustering, captured CTC from human and mouse blood with a Parsortix GEN3D6.5 Cell Separation Cassette, and directly stained the captured CTC with EpCAM-AF488 (CellSignaling, Cat# CST5198), HER2-AF488 (#324410, BioLegend), EGFR-FITC (GeneTex, Cat# GTX11400) and CD45-BV605 (Biolegend, Cat# 304042 (anti-human); Cat# 103140 (anti-mouse)) antibodies [15].
FAST cytometry was developed to speed up the analyses of immunofluorescent-labeled cells in large volumes of peripheral blood (SRI International, Menlo Park, CA) [82, 83]. This system allows for the detection and isolation of CTCs from large volumes of peripheral blood. A laser printing technique is utilized to localize rare subpopulations of immunofluorescent-labeled cells on glass substrates. The laser printing optic has the ability to excite 300,000 cells per second and the emission spectrum is monitored on a very wide field of view. The scan rates of FAST analyses can be 500-fold faster than automated digital microscopy. The enhanced screening rate combined with the high sensitivity provides the desired performance for the detection in peripheral blood of early-stage tumors. The possibility to detect and isolate CTCs in a single step minimizes the chance of losing cells. FAST cytometry was used to monitor CTCs in the peripheral blood of patients with stage IV breast cancer.
A device termed CellSearch Circulating Tumor Cell Test is commercially available (Menarini-Silicon Biosystems, Bologna, Italy and San Diego, CA) and has been approved by the U.S. Food and Drug Administration (FDA) for clinical testing of blood samples of patients with breast cancer [16, 84, 85], colorectal cancer [86] and prostate cancer [87]. A ferrofluid linked to anti-EpCAM antibodies is utilized for the initial enrichment of EpCAM-positive cells. Subsequently, a magnetic field is applied for the isolation of the ferrofluid-EpCAM-positive cells complex. The CTCs detection is carried out with a pool of phycoerythrin (PE)-labelled anti-CK antibodies and allophycocyanin (APC)-labeled anti-CD45 antibodies, mixed with a nuclear dye (4′,6-diamidino-2-phenylindole (DAPI)) and a permeabilization buffer for the entry of anti-cytokeratin antibodies into the cells [88, 89]. Finally, immunofluorescence is carried out for the enumeration of EpCAM-positive CK-positive CD45-negative CTCs. All the above-mentioned components and reagents necessary for the CTCs analysis are included in the CellSearch Epithelial Cell kit (Veridex, Warren, NJ). The CellSearch system can only detect EpCAM-positive and CK-positive CTCs. This system is not suitable for CTCs that either do not express epithelial phenotypes, or have lost EpCAM and CK expression, due to advanced EMT.
CellSearch can also be augmented with a second approach such as the DEPArray technology to increase the chance of detecting CTCs [43].
ISET enriches epithelial cancer cells with a blood filtration, which takes place through a membrane that has pores with a diameter of 8 μm. Larger epithelial cancer cells remain on the filter and, therefore, can be stained either for immunocytochemistry, or cytomorphological analysis [90]. ISET has the ability to detect a single CTC from 1 ml of peripheral blood. ISET is commercially available (RareCells, Paris, France) and has been used for the detection of CTCs in blood samples of patients with tumors of the breast, lung and prostate. A comparative analysis revealed some discrepancies in the enumeration of CTCs between ISET and CellSearch. These discrepancies may be attributable to the heterogeneity of tumor cell size and/or to differential expression of EpCAM among cancer cells. The latter is a limitation of CellSearch, whereas the former is a drawback of the isolation by cell size.
This test is commercially available (AdnaGen AG, Langenhagen, Germany) and has been used for the analysis of CTCs in blood samples derived from patients with cancers of the breast, colon and prostate [91-93]. CTCs enrichment is conducted with magnetic separation of EpCAM-positive cells, whereas the detection is carried out by RT-PCR for the identification of tumor-associated transcripts. A clinical study conducted on patients with metastatic breast cancer used RT-PCR for the analysis of the following transcripts: GA733-2, MUC-1, and HER2. Both AdnaTest and CellSearch exhibited concordant data in terms of CTCs enumeration and sensitivity. Both systems were able to detect 2 CTCs in 7.5 ml of patient-derived peripheral blood. However, cells are no longer viable after the AdnaTest and, therefore, they cannot be used for other studies. In addition, RT-PCR techniques may provide false positives, because of nucleic acid-related contaminations.
EPISPOT detects specific secreted proteins and stands for epithelial immunospot, which derives from enzyme-linked immuno-assays [94]. An initial enrichment step is carried out by immunomagnetic depletion of CD45-positive cells, which is then followed by immunomagnetic positive enrichment by selecting CXCR4-positive cells. At this stage, only viable cells can secrete proteins for EPISPOT assay. MUC1 secretion was detected in 100% of patients with metastatic breast cancer, whereas PSA was observed in 83.3% of prostate cancer patients [95, 96]. This system is restricted to the analysis of CXCR4-positive CTCs and, therefore, CXCR4-negative CTCs are lost.
The Ariol system is commercially available (Genetix USA Inc, San Jose, CA, USA) and consists of an automated cell image capture for the analysis of CTCs placed on glass slides [97]. The protocol was set up for the analysis of blood samples of patients with breast cancer. For the enrichment step, peripheral blood is initially treated with a lysis buffer to remove erythrocytes (CTC Enrichment and Detection Kit, Genetix, New Milton, UK). Cells were then centrifuged at 700 × g for 10 minutes at room temperature and the cell pellet was gently resuspended with 0.5 ml dilution buffer (Carcinoma Cell Enrichment and Detection Kit, Miltenyi Biotec, Bergisch Gladbach, Germany). Cell blocking, permeation and fixation were carried out following the manufacturer’s instructions (Carcinoma Cell Enrichment and Detection Kit, Miltenyi Biotec, Bergisch Gladbach, Germany). CTCs enrichment was carried out with anti-CK antibodies either alone, or in combination with anti-EpCAM antibodies, following the instructions of the CTC Enrichment and Detection Kit (Genetix, New Milton, UK). As further controls, labeled anti-CD45 antibodies and DAPI were included in the assay [97]. A Leica DM6000 with software for clinical breast cancer panel analysis was utilized for image capture (Leica Microsystems, Wetzlar, Germany). The Ariol system allows for the detection of CK-positive EpCAM-positive and CK-positive EpCAM-negative CTCs. However, cells are not viable after the Ariol system assay.
- Gkountela S, Szczerba B, Donato C, Aceto N. Recent advances in the biology of human circulating tumour cells and metastasis. ESMO Open. 2016;1:e000078 pubmed
- Banys Paluchowski M, Krawczyk N, Fehm T. Potential Role of Circulating Tumor Cell Detection and Monitoring in Breast Cancer: A Review of Current Evidence. Front Oncol. 2016;6:255 pubmed
- Mu Z, Benali Furet N, Uzan G, Znaty A, Ye Z, Paolillo C, et al. Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer. Int J Mol Sci. 2016;17: pubmed
- Millner L, Linder M, Valdes R. Circulating tumor cells: a review of present methods and the need to identify heterogeneous phenotypes. Ann Clin Lab Sci. 2013;43:295-304 pubmed
- Zieglschmid V, Hollmann C, Bocher O. Detection of disseminated tumor cells in peripheral blood. Crit Rev Clin Lab Sci. 2005;42:155-96 pubmed
- Ross A, Cooper B, Lazarus H, Mackay W, Moss T, Ciobanu N, et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood. 1993;82:2605-10 pubmed
- Litvinov S, van Driel W, van Rhijn C, Bakker H, van Krieken H, Fleuren G, et al. Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation. Am J Pathol. 1996;148:865-75 pubmed
- Franke W, Schmid E, Osborn M, Weber K. Intermediate-sized filaments of human endothelial cells. J Cell Biol. 1979;81:570-80 pubmed
- Mattey D, Nixon N, Wynn Jones C, Dawes P. Demonstration of cytokeratin in endothelial cells of the synovial microvasculature in situ and in vitro. Br J Rheumatol. 1993;32:676-82 pubmed
- Noble P, Cutts J. Separation of blood leukocytes by Ficoll gradient. Can Vet J. 1967;8:110-1 pubmed
- Noble P, Cutts J, Carroll K. Ficoll flotation for the separation of blood leukocyte types. Blood. 1968;31:66-73 pubmed
- Gertler R, Rosenberg R, Fuehrer K, Dahm M, Nekarda H, Siewert J. Detection of circulating tumor cells in blood using an optimized density gradient centrifugation. Recent Results Cancer Res. 2003;162:149-55 pubmed
- Zheng S, Lin H, Liu J, Balic M, Datar R, Cote R, et al. Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. J Chromatogr A. 2007;1162:154-61 pubmed
- Marrinucci D, Bethel K, Bruce R, Curry D, Hsieh B, Humphrey M, et al. Case study of the morphologic variation of circulating tumor cells. Hum Pathol. 2007;38:514-9 pubmed
- Zigeuner R, Riesenberg R, Pohla H, Hofstetter A, Oberneder R. Isolation of circulating cancer cells from whole blood by immunomagnetic cell enrichment and unenriched immunocytochemistry in vitro. J Urol. 2003;169:701-5 pubmed
- Stelzer G, Shults K, Loken M. CD45 gating for routine flow cytometric analysis of human bone marrow specimens. Ann N Y Acad Sci. 1993;677:265-80 pubmed
- Tong X, Xiong Y, Zborowski M, Farag S, Chalmers J. A novel high throughput immunomagnetic cell sorting system for potential clinical scale depletion of T cells for allogeneic stem cell transplantation. Exp Hematol. 2007;35:1613-22 pubmed
- Nagrath S, Sequist L, Maheswaran S, Bell D, Irimia D, Ulkus L, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450:1235-9 pubmed
- Rao C, Chianese D, Doyle G, Miller M, Russell T, Sanders R, et al. Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int J Oncol. 2005;27:49-57 pubmed
- Radovich M, Jiang G, Hancock B, Chitambar C, Nanda R, Falkson C, et al. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial. JAMA Oncol. 2020;: pubmed publisher
- Gomella L, Raj G, Moreno J. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. J Urol. 1997;158:326-37 pubmed
- Raj G, Moreno J, Gomella L. Utilization of polymerase chain reaction technology in the detection of solid tumors. Cancer. 1998;82:1419-42 pubmed
- Smith B, Slade M, English J, Graham H, Lüchtenborg M, Sinnett H, et al. Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantitative polymerase chain reaction and immunocytochemical techniques. J Clin Oncol. 2000;18:1432-9 pubmed
- de Cremoux P, Extra J, Denis M, Pierga J, Bourstyn E, Nos C, et al. Detection of MUC1-expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by real-time polymerase chain reaction. Clin Cancer Res. 2000;6:3117-22 pubmed
- Louha M, Poussin K, Ganne N, Zylberberg H, Nalpas B, Nicolet J, et al. Spontaneous and iatrogenic spreading of liver-derived cells into peripheral blood of patients with primary liver cancer. Hepatology. 1997;26:998-1005 pubmed
- Wu C, Lin S, Yu F, Wu D, Pan Y, Hsieh J, et al. Development of a high-throughput membrane-array method for molecular diagnosis of circulating tumor cells in patients with gastric cancers. Int J Cancer. 2006;119:373-9 pubmed
- Hardingham J, Hewett P, Sage R, Finch J, Nuttall J, Kotasek D, et al. Molecular detection of blood-borne epithelial cells in colorectal cancer patients and in patients with benign bowel disease. Int J Cancer. 2000;89:8-13 pubmed
- Moreno J, Croce C, Fischer R, Monne M, Vihko P, Mulholland S, et al. Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res. 1992;52:6110-2 pubmed
- Olsson C, de Vries G, Buttyan R, Katz A. Reverse transcriptase-polymerase chain reaction assays for prostate cancer. Urol Clin North Am. 1997;24:367-78 pubmed
- Kurek R, Nunez G, Tselis N, Konrad L, Martin T, Roeddiger S, et al. Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients. Clin Cancer Res. 2004;10:5808-14 pubmed
- Kowalewska M, Chechlinska M, Markowicz S, Kober P, Nowak R. The relevance of RT-PCR detection of disseminated tumour cells is hampered by the expression of markers regarded as tumour-specific in activated lymphocytes. Eur J Cancer. 2006;42:2671-4 pubmed
- Feldman B, Ebrahim S, Hazan S, Gyi K, Johnson M, Johnson A, et al. Routine prenatal diagnosis of aneuploidy by FISH studies in high-risk pregnancies. Am J Med Genet. 2000;90:233-8 pubmed
- Evans M, Sharp M, Tepperberg J, Kilpatrick M, Tsipouras P, Tafas T. Automated microscopy of amniotic fluid cells: detection of FISH signals using the FastFISH imaging system. Fetal Diagn Ther. 2006;21:523-7 pubmed
- Kilpatrick M, Tafas T, Evans M, Jackson L, Antsaklis A, Brambati B, et al. Automated detection of rare fetal cells in maternal blood: eliminating the false-positive XY signals in XX pregnancies. Am J Obstet Gynecol. 2004;190:1571-8; discussion 1578-81 pubmed
- Mattanovich D, Borth N. Applications of cell sorting in biotechnology. Microb Cell Fact. 2006;5:12 pubmed
- Hsieh H, Marrinucci D, Bethel K, Curry D, Humphrey M, Krivacic R, et al. High speed detection of circulating tumor cells. Biosens Bioelectron. 2006;21:1893-9 pubmed
- Krivacic R, Ladanyi A, Curry D, Hsieh H, Kuhn P, Bergsrud D, et al. A rare-cell detector for cancer. Proc Natl Acad Sci U S A. 2004;101:10501-4 pubmed
- Moussavi Harami S, Wisinski K, Beebe D. Circulating Tumor Cells in Metastatic Breast Cancer: A Prognostic and Predictive Marker. J Patient Cent Res Rev. 2014;1:85-92 pubmed
- Wang F, Yang X, Yang S, Wang B, Feng M, Tu J. A higher number of circulating tumor cells (CTC) in peripheral blood indicates poor prognosis in prostate cancer patients--a meta-analysis. Asian Pac J Cancer Prev. 2011;12:2629-35 pubmed
- Racila E, Euhus D, Weiss A, Rao C, McConnell J, Terstappen L, et al. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci U S A. 1998;95:4589-94 pubmed
- Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007;13:920-8 pubmed
- Todenhöfer T, Hennenlotter J, Feyerabend S, Aufderklamm S, Mischinger J, Kühs U, et al. Preliminary experience on the use of the Adnatest® system for detection of circulating tumor cells in prostate cancer patients. Anticancer Res. 2012;32:3507-13 pubmed
- Hauch S, Zimmermann S, Lankiewicz S, Zieglschmid V, Böcher O, Albert W. The clinical significance of circulating tumour cells in breast cancer and colorectal cancer patients. Anticancer Res. 2007;27:1337-41 pubmed
- Alix Panabières C, Vendrell J, Pellé O, Rebillard X, Riethdorf S, Muller V, et al. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem. 2007;53:537-9 pubmed
- Alix Panabières C, Brouillet J, Fabbro M, Yssel H, Rousset T, Maudelonde T, et al. Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. J Immunol Methods. 2005;299:177-88 pubmed
- Alix Panabières C, Muller V, Pantel K. Current status in human breast cancer micrometastasis. Curr Opin Oncol. 2007;19:558-63 pubmed
- Materials and Methods [ISSN : 2329-5139] is a unique online journal with regularly updated review articles on laboratory materials and methods. If you are interested in contributing a manuscript or suggesting a topic, please leave us feedback.
- method
- 3D Cell Culture: A Review
- Activators and Inhibitors in Cell Biology Research
- Apoptosis Assays
- Cell Isolation
- Cell Markers
- Flow Cytometry and Cell Sorting: A Practical Guide
- Incorporating Unnatural Amino Acids into Recombinant Proteins in Living Cells
- Live Cell Imaging
- Neuronal Cell Markers
- Single Cell Technologies
- Somatic Mutations
- Stem Cell Markers
- Stem Cell Research Using Mouse Models
- Stem Cells
- The Cell Cycle Analysis
- Tumor Markers Currently Utilized in Cancer Care